PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Official Title

An Open-lable, Single Arm, Single Center, Phase 2 Study of PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell

Brief Summary

      This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and
      safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell
      lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety
      evaluations (both clinical and laboratory) are performed at baseline, before each study
      treatment, and throughout the study.

Detailed Description

      The primary objective of this phase 2 study is to assess objective response rate of SHR-1210
      combined with Apatinib in patients with relapsed or refractory NK/T cell lymphoma. The
      secondary objective is to observe time to response,progression free survival rate at 2
      years,overall survival rate at 2 years,safety and immunogenicity of SHR-1210 combined with
      Apatinib in relapsed or refractory NK/T cell lymphoma.

Study Phase

Phase 2

Study Type


Primary Outcome

objective response rate


NK/T-cell Lymphoma



Study Arms / Comparison Groups

 SHR1210 +Apatinib
Description:  SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 20, 2018

Completion Date

June 30, 2021

Primary Completion Date

March 30, 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Histologically confirmed extranodal NK/T cell lymphoma nasal, PTCL,NOS, AITL, ALCL;

          2. Subjects must be recurrent or refractory, and 10-15 white tumors of tumor tissue
             should be provided.

          3. Subjects enrolled have measurable lesion(s) according to Lugano 2014 criteria

          4. ECOG performance status of 0 or 1;

        6.Life expectancy ≥ 12 weeks.; 7.Adequate laboratory parameters during the screening period
        as evidenced by the following:

        a.Absolute neutrophil count ≥ 1.5× 109/L ; b.Platelets ≥ 100 × 109/L; c.Hemoglobin ≥ 9.0
        g/dL; d.Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), ALT and AST ≤ 2.5×ULN
        e.Serum Creatinine ≤1.25×ULN or Creatinine clearance≥45 mL/min; f.Coagulation function
        index:INR ≤1.5×ULN,APTT≤1.5×ULN 8.Women of childbearing potential must be willing and able
        to employ a highly effective method of birth control/contraception to prevent pregnancy
        while on treatment and for at least 120 days after receiving the last dose of study
        treatment. Women of childbearing potential with pregnancy test negative within 7days before
        entering the group and not in in lactation; Male subjects with WOCBP partner should receive
        Surgical sterilization orconsent to employ a highly effective method of birth
        control/contraception to prevent pregnancy while on treatment and for at least 120 days
        after receiving the last dose of study treatment.

        9.Able to understand and sign an informed consent form (ICF).

        Exclusion Criteria:

          1. Known central nervous system lymphoma

          2. Haemophilus cell syndrome at diagnosis

          3. Large lung vessels were involved

          4. History and complication

               1. Active, known or suspected autoimmune disease. Subjects who were in a stable
                  state without systemic immunosuppressive therapy were admitted

               2. Subjects requiring systemic treatment with corticosteroids (> 10 mg/day
                  prednisone or equivalent) or other immunosuppressive agents were given the study
                  drug within 14 days prior to administration. Inhaled or topical corticosteroids
                  and adrenaline replacement at a therapeutic dose of more than 10 mg/day
                  prednisone are allowed in the absence of active autoimmune disease

               3. Recieved anti-tumor vaccines or other anti-tumor therapy with immune stimulation
                  within 3 months.

               4. Prior exposure to any PD-1/PD-L1/PD -L 2 or CTLA -4 antibody .

               5. Participating in other clinical studies or less than 4 weeks before the end of a
                  clinical trial;

               6. Known and suspicion of interstitial pneumonia

               7. History of other malignancies except in patients with basal cell carcinoma of the
                  skin, superficial bladder, squamous cell carcinoma of the skin, or carcinoma of
                  the cervix in situ who had undergone potential curable treatment and had no
                  recurrence within five years of initiation of self-treatment;

               8. Received chemotherapy, radiotherapy,immunotherapy, including topical therapy
                  within 4 weeks. Previous anti-tumor therapy related adverse reactions (except
                  trichomadesis) did not recover to CTCAE ≤1.

               9. Prior allo-HSCT.

              10. ASCT within 90 days.

              11. Impact of major surgery or severe trauma had been eliminated for less than 14

              12. Active pulmonary tuberculosis.

              13. Severe acute or chronic infection requiring systemic therapy.

              14. In the first 2 months before treatment, there was a significant amount of half a
                  teaspoon (2.5ml) of blood or hemoptysis

              15. Significant clinical symptoms of bleeding or a clear tendency to bleed occurred
                  within the first three months of randomization, such as gastrointestinal
                  bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ or above, or
                  vasculitis, etc;

              16. Arteriovenous thrombotic events, such as cerebral vascular accidents (including
                  transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein
                  thrombosis, and pulmonary embolism, occurred within the first six months of

              17. Known hereditary or acquired bleeding and thrombotic tendencies ;

              18. Suffering from hypertension, and the treatment of hypotensive drugs can not get
                  good control.(systolic blood pressure is greater than 140 mmHg or diastolic
                  pressure is more than 90 mmHg);

              19. Suffering from heart failure (New York Heart Association standard III or IV) and
                  given appropriate medical treatment.Uncontrolled coronary artery disease and
                  arrhythmia. History of myocardial infarction within 6 months;

              20. Live vaccinations were given within four weeks before the study drug was
                  administered. Inactivated viral vaccines for seasonal influenza were allowed, but
                  live attenuated influenza vaccines for intranasal use were not allowed.

          5. laboratory test

               1. known HIV positive or known AIDS.

               2. Untreated active hepatitis; Hepatitis B and hepatitis C infection in common.

               3. Abnormal coagulation function (PT > 16s, APTT > 43s, TT > 21s, Fbg < 2G / L)
                  having tends to bleed or is undergoing thrombolytic or anticoagulant therapy;

               4. Routine urine tests indicate that urine protein is more than + +, or 24 hours
                  urine protein is more than 1 g.

          6. Other factors that may lead to the study termination, such as severe disease or
             abnormal laboratory tests or family or social factors affecting subjects safety or
             test data and sample collection

          7. Women suffering from pregnancy or lactation.




18 Years - 100 Years

Accepts Healthy Volunteers



Yuqin Song, +13683398726, [email protected]

Administrative Informations



Organization ID

SHR-1210-APTN-IIT-NKT lymphoma

Responsible Party

Principal Investigator

Study Sponsor

Peking University

Study Sponsor

Yuqin Song, Principal Investigator, Cancer Hospital of Beijing University

Verification Date

October 2018